TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Wang, Chao ^a,b   Cao, Shouqiang ^a   Yan, Ying ^a   Ying, Qiao ^a   Jiang, Tao ^b   Xu, Ke ^a   Wu, Anhua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Beijing Neurosurgical Institution   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; MESSENGER RNA; OLIGODEOXYRIBONUCLEOTIDE; TLR9 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER PATIENT; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION FUNCTION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; ADULT; BRAIN TUMOR; CELL ADHESION; CELL MOTION; DISEASE COURSE; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; OLIGODEOXYRIBONUCLEOTIDES; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TOLL-LIKE RECEPTOR 9;

EID: 77955288686     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-415     Document Type: Article

References (45)

1. Bondy ML, Scheurer ME, Malmer B, Barnholtz-Sloan JS, Davis FG, Il'yasova D, Kruchko C, McCarthy BJ, Rajaraman P, Schwartzbaum JA, et al. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer 2008, 113(7 Suppl):1953-1968. 10.1002/cncr.23741, 2861559, 18798534.
2. Walker PR, Calzascia T, de Tribolet N, Dietrich PY. T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res Brain Res Rev 2003, 42(2):97-122. 10.1016/S0165-0173(03)00141-3, 12738053.
3. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev 2009, 61(3):195-204. 10.1016/j.addr.2008.12.008, 19211030.
4. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001, 194(6):863-869. 10.1084/jem.194.6.863, 2195968, 11561001.
5. Boonstra A, Rajsbaum R, Holman M, Marques R, Asselin-Paturel C, Pereira JP, Bates EEM, Akira S, Vieira P, Liu Y-J, et al. Macrophages and Myeloid Dendritic Cells, but Not Plasmacytoid Dendritic Cells, Produce IL-10 in Response to MyD88- and TRIF-Dependent TLR Signals, and TLR-Independent Signals. J Immunol 2006, 177(11):7551-7558.
6. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA 1996, 93(7):2879-2883. 10.1073/pnas.93.7.2879, 39727, 8610135.
7. Ilvesaro JM, Merrell MA, Li L, Wakchoure S, Graves D, Brooks S, Rahko E, Jukkola-Vuorinen A, Vuopala KS, Harris KW, et al. Toll-like receptor 9 mediates CpG oligonucleotide induced cellular invasion. Mol Cancer Res 2008, 6(10):1534-1543. 10.1158/1541-7786.MCR-07-2005, 18922969.
8. Schmausser B, Andrulis M, Endrich S, Muller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol 2005, 295(3):179-185. 10.1016/j.ijmm.2005.02.009, 16044857.
9. Droemann D, Albrecht D, Gerdes J, Ulmer A, Branscheid D, Vollmer E, Dalhoff K, Zabel P, Goldmann T. Human lung cancer cells express functionally active Toll-like receptor 9. Respiratory Research 2005, 6(1):1.. 10.1186/1465-9921-6-1, 544843, 15631627.
10. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW, Selander KS. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007, 67(7):774-781. 10.1002/pros.20562, 17373717.
11. Merrell MA, Ilvesaro JM, Lehtonen N, Sorsa T, Gehrs B, Rosenthal E, Chen D, Shackley B, Harris KW, Selander KS. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006, 4(7):437-447. 10.1158/1541-7786.MCR-06-0007, 16849519.
12. Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, Xu L. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther 2007, 6(11):1704-1709. 10.4161/cbt.6.11.4826, 17986857.
13. Grauer OM, Molling JW, Bennink E, Toonen LWJ, Sutmuller RPM, Nierkens S, Adema GJ. TLR Ligands in the Local Treatment of Established Intracerebral Murine Gliomas. J Immunol 2008, 181(10):6720-6729.
14. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006, 54(6):526-535. 10.1002/glia.20401, 16906541.
15. Ginzkey C, Eicker SO, Marget M, Krause J, Brecht S, Westphal M, Hugo HH, Mehdorn HM, Steinmann J, Hamel W. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model. Cancer Immunol Immunother 2009, 59(4):541-51. 10.1007/s00262-009-0771-y, 19798500.
16. Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother 2007, 30(8):789-797. 10.1097/CJI.0b013e318155a0f6, 18049330.
17. Meng Y, Kujas M, Marie Y, Paris S, Thillet J, Delattre JY, Carpentier AF. Expression of TLR9 within human glioblastoma. J Neurooncol 2008, 88(1):19-25. 10.1007/s11060-008-9536-2, 18253698.
18. Kononen J, Bubendorf L, Kallionimeni A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallionimeni O-P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4(7):844-847. 10.1038/nm0798-844, 9662379.
19. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol 2002, 32(7):1958-1968. 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U, 12115616.
20. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002, 168(9):4531-4537.
21. Yasuda H, Leelahavanichkul A, Tsunoda S, Dear JW, Takahashi Y, Ito S, Hu X, Zhou H, Doi K, Childs R, et al. Chloroquine and inhibition of Toll-like receptor 9 protect from sepsis-induced acute kidney injury. Am J Physiol Renal Physiol 2008, 294(5):F1050-1058. 10.1152/ajprenal.00461.2007, 2386262, 18305095.
22. Ohgaki H, Kleihues P. Population-Based Studies on Incidence, Survival Rates, and Genetic Alterations in Astrocytic and Oligodendroglial Gliomas. Journal of Neuropathology & Experimental Neurology 2005, 64(6):479-489.
23. Scheurer ME, Bondy ML, Aldape KD, Albrecht T, El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol 2008, 116(1):79-86. 10.1007/s00401-008-0359-1, 18351367.
24. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ. Human Cytomegalovirus Infection and Expression in Human Malignant Glioma. Cancer Res 2002, 62(12):3347-3350.
25. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-oncol 2008, 10(1):10-18. 10.1215/15228517-2007-035, 2600830, 17951512.
26. Iversen A-C, Steinkjer B, Nilsen N, Bohnhorst J, Moen SH, Vik R, Stephens P, Thomas DW, Benedict CA, Espevik T. A Proviral Role for CpG in Cytomegalovirus Infection. J Immunol 2009, 182(9):5672-5681. 10.4049/jimmunol.0801268, 19380814.
27. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol 2004, 25(7):381-386. 10.1016/j.it.2004.04.011, 15207506.
28. Takeshita F, Gursel I, Ishii KJ, Suzuki K, Gursel M, Klinman DM. Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol 2004, 16(1):17-22. 10.1016/j.smim.2003.10.009, 14751759.
29. Rayburn ER, Wang W, Zhang R, Wang H. Experimental therapy for colon cancer: anti-cancer effects of TLR9 agonism, combination with other therapeutic modalities, and dependence upon p53. Int J Oncol 2007, 30(6):1511-1519.
30. Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li G, Qiu X, Zhang W, Song SW. Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol 2009, 11(5):468-476. 10.1215/15228517-2008-114, 19164435.
31. Sanai N, Berger MS. Operative techniques for gliomas and the value of extent of resection. Neurotherapeutics 2009, 6(3):478-486. 10.1016/j.nurt.2009.04.005, 19560738.
32. Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 1999, 42(3):227-231. 10.1023/A:1006118018770, 10433106.
33. Pang BC, Wan WH, Lee CK, Khu KJ, Ng WH. The role of surgery in high-grade glioma--is surgical resection justified? A review of the current knowledge. Ann Acad Med Singapore 2007, 36(5):358-363.
34. Chinnaiyan P, Wang M, Rojiani AM, Tofilon PJ, Chakravarti A, Ang KK, Zhang HZ, Hammond E, Curran W, Mehta MP. The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group. Radiat Oncol 2008, 3:32. 10.1186/1748-717X-3-32, 2563009, 18817556.
35. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, Nikkhah G. BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer 10:30. 10.1186/1471-2407-10-30, 2837009, 20122270.
36. Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis DN. Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004, 10(1 Pt 1):228-233. 10.1158/1078-0432.CCR-0841-3, 14734474.
37. Jukkola-Vuorinen A, Rahko E, Vuopala KS, Desmond R, Lehenkari PP, Harris KW, Selander KS. Toll-Like Receptor-9 Expression Is Inversely Correlated with Estrogen Receptor Status in Breast Cancer. Journal of Innate Immunity 2009, 1(1):59-68.
38. Lee J-W, Choi J-J, Seo ES, Kim MJ, Kim WY, Choi CH, Kim T-J, Kim B-G, Song SY, Bae D-S. Increased toll-like receptor 9 expression in cervical neoplasia. Molecular Carcinogenesis 2007, 46(11):941-947. 10.1002/mc.20325, 17440926.
39. Briceno E, Calderon A, Sotelo J. Institutional experience with chloroquine as an adjuvant to the therapy for glioblastoma multiforme. Surg Neurol 2007, 67(4):388-391. 10.1016/j.surneu.2006.08.080, 17350410.
40. Briceno E, Reyes S, Sotelo J. Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine. Neurosurg Focus 2003, 14(2):e3.. 10.3171/foc.2003.14.2.4, 15727424.
41. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A, Martin-Duverneuil N, Sanson M, Lacomblez L, Taillibert S, et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncol 2006, 8(1):60-66. 10.1215/S1522851705000475, 1871923, 16443949.
42. Carpentier AF, Xie J, Mokhtari K, Delattre JY. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 2000, 6(6):2469-2473.
43. Ginzkey C, Eicker SO, Marget M, Krause J, Brecht S, Westphal M, Hugo HH, Mehdorn HM, Steinmann J, Hamel W. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model. Cancer Immunol Immunother 59(4):541-551. 10.1007/s00262-009-0771-y, 19798500.
44. Deng G-M, Liu Z-Q, Tarkowski A. Intracisternally Localized Bacterial DNA Containing CpG Motifs Induces Meningitis. J Immunol 2001, 167(8):4616-4626.
45. Carpentier A, Metellus P, Ursu R, Zohar S, Lafitte F, Barrie M, Meng Y, Richard M, Parizot C, Laigle-Donadey F, et al. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 12(4):401-408.